Preterm Donor Human Milk Supplementation of Mother's Own Milk in VLBW Infants

NCT ID: NCT05675397

Last Updated: 2023-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective randomized controlled trial aims to investigate whether feeding very low birth weight (VLBW) infants with Mother's own milk (MOM) supplemented with either preterm (PDM) or term donor milk (TDM), when MOM is insufficient, has a positive impact on infants' protein intake, growth and morbidity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mother's own milk (MOM) is the optimal nutrition for preterm infants. When MOM is not sufficient, pasteurized donor milk (DM) is the best alternative according to current recommendations. Donor milk is primarily derived from mothers of term-born infants for the first six months of lactation. However, this term milk presents significant differences compared to preterm human milk which has higher protein concentration and more caloric energy.

The investigators hypothesized that feeding VLBW infants with preterm donor milk (PDM) in combination with MOM may positively influence the protein intake and, consequently, the infants' growth. The aim of the current study is to assess whether MOM supplementation with PDM has any beneficial effects on the nutrition, growth and morbidity in VLBW infants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MOM supplemented with PDM (group A)

VLBW Infants fed with mother's own milk (MOM) supplemented with preterm donor milk (PDM)

Group Type EXPERIMENTAL

donor human milk

Intervention Type DIETARY_SUPPLEMENT

Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding

MOM supplemented with TDM (group B)

VLBW infants fed with mother's own milk (MOM) supplemented with term donor milk (TDM)

Group Type ACTIVE_COMPARATOR

donor human milk

Intervention Type DIETARY_SUPPLEMENT

Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

donor human milk

Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• VLBW infants with birth weight \<1500g born to mothers who agree to provide donor milk for the first three weeks of life (donor milk period) if their own milk quantity is insufficient

Exclusion Criteria

* Congenital anomalies
* Chromosomal disorders
* Metabolic diseases
* Feeding with formula at any point during the first 3 weeks of life (donor milk period)
Minimum Eligible Age

1 Day

Maximum Eligible Age

3 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National and Kapodistrian University of Athens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Soultana (Tania) Siahanidou

Professor in Pediatrics-Neonatology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

George Liosis, MD, PhD

Role: STUDY_CHAIR

Neonatal Intensive Care Unit, "Elena Venizelou" General and Maternal Hospital, Athens, 11521, Greece

Giannoula Gialeli

Role: PRINCIPAL_INVESTIGATOR

Neonatal Intensive Care Unit, "Elena Venizelou" General and Maternal Hospital, Athens, 11521, Greece

Tania Siahanidou

Role: STUDY_DIRECTOR

First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neonatal Intensive Care Unit, "Elena Venizelou" General and Maternal Hospital

Athens, , Greece

Site Status RECRUITING

First Department of Pediatrics, National and Kapodistrian University of Athens

Athens, , Greece

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tania Siahanidou, MD, PhD

Role: CONTACT

+30 2132013517

Giannoula Gialeli, MD

Role: CONTACT

+30 2109758491

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giannoula Gialeli, MD

Role: primary

+30 2109758491

Anastasia Kapetanaki, MD

Role: backup

+302132051000

Tania Siahanidou, MD, PhD

Role: primary

+30 2132013517

References

Explore related publications, articles, or registry entries linked to this study.

Gialeli G, Kapetanaki A, Panagopoulou O, Vourna P, Michos A, Kanaka-Gantenbein C, Liosis G, Siahanidou T. Supplementation of Mother's Own Milk with Preterm Donor Human Milk: Impact on Protein Intake and Growth in Very Low Birth Weight Infants-A Randomized Controlled Study. Nutrients. 2023 Jan 21;15(3):566. doi: 10.3390/nu15030566.

Reference Type DERIVED
PMID: 36771273 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6116

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

OptiMoM Kindergarten Study
NCT02759809 COMPLETED
Human Milk in Preterm Infants
NCT05228535 UNKNOWN NA